Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker BCAX
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 24,777 | $449.0K | — | Oct 21, 2026 | — | Form 144 ↗ |
| Sep 8, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 12,500 | $283.0K | 10b5-1 | Sep 8, 2026 | — | Form 144 ↗ |
| Sep 8, 2026 | Ryan Cohlhepp Officer, Director | BCAX Bicara Therapeutics Inc. | 17,500 | $396.2K | 10b5-1 | Sep 8, 2026 | Form 4 ↗ 2 days later · 17,500 shares | Form 144 ↗ |
| Aug 10, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 12,500 | $347.9K | 10b5-1 | Aug 10, 2026 | Form 4 ↗ 2 days later · 12,500 shares | Form 144 ↗ |
| Aug 10, 2026 | Ryan Cohlhepp Officer, Director | BCAX Bicara Therapeutics Inc. | 18,750 | $521.8K | 10b5-1 | Aug 10, 2026 | Form 4 ↗ 2 days later · 18,750 shares | Form 144 ↗ |
| Aug 10, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 10,000 | $278.3K | 10b5-1 | Aug 10, 2026 | Form 4 ↗ 2 days later · 10,000 shares | Form 144 ↗ |
| Jul 10, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 10,000 | $296.8K | 10b5-1 | Jul 10, 2026 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| Jul 8, 2026 | Ryan Cohlhepp Officer, Director | BCAX Bicara Therapeutics Inc. | 28,750 | $869.7K | 10b5-1 | Jul 8, 2026 | Form 4 ↗ 2 days later · 28,750 shares | Form 144 ↗ |
| Jul 8, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 28,000 | $847.0K | 10b5-1 | Jul 8, 2026 | Form 4 ↗ 2 days later · 28,000 shares | Form 144 ↗ |
| Jul 8, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 50,000 | $1.4M | — | Jul 8, 2026 | — | Form 144 ↗ |
| Jul 7, 2026 | Lara Meisner Officer | BCAX Bicara Therapeutics Inc. | 1,000 | $29.8K | — | Jul 7, 2026 | — | Form 144 ↗ |
| Jun 25, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 50,000 | $1.3M | — | Jun 25, 2026 | — | Form 144 ↗ |
| Jun 1, 2026 | Meisner Lara Former Chief Legal Officer | BCAX Bicara Therapeutics Inc. | 71,390 | $1.5M | — | Jun 1, 2026 | — | Form 144 ↗ |
| May 26, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 5,500 | $120.0K | 10b5-1 | May 26, 2026 | — | Form 144 ↗ |
| May 21, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 9,200 | $187.9K | 10b5-1 | May 21, 2026 | Form 4 ↗ 5 days later · 9,200 shares | Form 144 ↗ |
| May 18, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 15,000 | $313.8K | 10b5-1 | May 18, 2026 | Form 4 ↗ 2 days later · 15,000 shares | Form 144 ↗ |
| May 15, 2026 | Ryan Cohlhepp Officer, Director | BCAX Bicara Therapeutics Inc. | 12,500 | $253.9K | 10b5-1 | May 15, 2026 | Form 4 ↗ 3 days later · 12,500 shares | Form 144 ↗ |
| Apr 27, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 5,500 | $125.8K | 10b5-1 | Apr 27, 2026 | Form 4 ↗ 1 day later · 5,500 shares | Form 144 ↗ |
| Apr 21, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 9,200 | $213.2K | 10b5-1 | Apr 21, 2026 | Form 4 ↗ 1 day later · 9,200 shares | Form 144 ↗ |
| Apr 20, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 15,000 | $356.1K | 10b5-1 | Apr 20, 2026 | Form 4 ↗ same day · 15,000 shares | Form 144 ↗ |
| Apr 15, 2026 | Ryan Cohlhepp Officer, Director | BCAX Bicara Therapeutics Inc. | 12,500 | $287.3K | 10b5-1 | Apr 15, 2026 | Form 4 ↗ 2 days later · 12,500 shares | Form 144 ↗ |
| Mar 25, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 5,500 | $104.2K | 10b5-1 | Mar 25, 2026 | Form 4 ↗ 1 day later · 5,500 shares | Form 144 ↗ |
| Mar 23, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 9,200 | $171.1K | 10b5-1 | Mar 23, 2026 | Form 4 ↗ 1 day later · 9,200 shares | Form 144 ↗ |
| Mar 20, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 1,596 | $30.2K | 10b5-1 | Mar 20, 2026 | Form 4 ↗ same day · 15,000 shares | Form 144 ↗ |
| Mar 19, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 6,905 | $129.7K | 10b5-1 | Mar 19, 2026 | Form 4 ↗ 1 day later · 15,000 shares | Form 144 ↗ |
| Mar 18, 2026 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 6,499 | $124.7K | 10b5-1 | Mar 18, 2026 | Form 4 ↗ 2 days later · 15,000 shares | Form 144 ↗ |
| Mar 16, 2026 | Ryan Cohlhepp Officer, Director | BCAX Bicara Therapeutics Inc. | 12,500 | $241.8K | 10b5-1 | Mar 16, 2026 | Form 4 ↗ 1 day later · 12,500 shares | Form 144 ↗ |
| Mar 9, 2026 | Claire Mazumdar Officer | BCAX Bicara Therapeutics Inc. | 36,766 | $704.7K | 10b5-1 | Mar 9, 2026 | Form 4 ↗ 2 days later · 36,766 shares | Form 144 ↗ |
| Mar 6, 2026 | Claire Mazumdar Officer | BCAX Bicara Therapeutics Inc. | 3,817 | $75.6K | 10b5-1 | Mar 6, 2026 | Form 4 ↗ same day · 8,234 shares | Form 144 ↗ |
| Mar 5, 2026 | Claire Mazumdar Officer | BCAX Bicara Therapeutics Inc. | 1,786 | $33.5K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 1 day later · 8,234 shares | Form 144 ↗ |
| Mar 4, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 2,963 | $54.1K | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 1 day later · 16,518 shares | Form 144 ↗ |
| Mar 4, 2026 | Claire Mazumdar Officer | BCAX Bicara Therapeutics Inc. | 2,631 | $49.3K | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 8,234 shares | Form 144 ↗ |
| Mar 4, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 16,300 | $301.9K | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 1 day later · 16,500 shares | Form 144 ↗ |
| Mar 3, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 13,555 | $246.9K | 10b5-1 | Mar 3, 2026 | Form 4 ↗ 2 days later · 16,518 shares | Form 144 ↗ |
| Mar 3, 2026 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 200 | $3,690 | 10b5-1 | Mar 3, 2026 | Form 4 ↗ 2 days later · 16,500 shares | Form 144 ↗ |
| Mar 3, 2026 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 17,392 | $315.9K | 10b5-1 | Mar 3, 2026 | Form 4 ↗ 2 days later · 17,392 shares | Form 144 ↗ |
| Feb 25, 2026 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 3,631 | $65.5K | 10b5-1 | Feb 25, 2026 | Form 4 ↗ 2 days later · 3,631 shares | Form 144 ↗ |
| Jan 22, 2026 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 3,828 | $65.0K | 10b5-1 | Jan 22, 2026 | Form 4 ↗ 4 days later · 3,828 shares | Form 144 ↗ |
| Jan 22, 2026 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 1,882 | $34.2K | 10b5-1 | Jan 22, 2026 | Form 4 ↗ 4 days later · 1,882 shares | Form 144 ↗ |
| Jan 15, 2026 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 149 | $2,685 | 10b5-1 | Jan 15, 2026 | Form 4 ↗ 5 days later · 149 shares | Form 144 ↗ |
| Dec 22, 2025 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 9,200 | $164.4K | 10b5-1 | Dec 22, 2025 | Form 4 ↗ 1 day later · 9,200 shares | Form 144 ↗ |
| Dec 15, 2025 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 12,500 | $233.8K | 10b5-1 | Dec 15, 2025 | Form 4 ↗ 1 day later · 12,500 shares | Form 144 ↗ |
| Nov 25, 2025 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 5,500 | $103.6K | 10b5-1 | Nov 25, 2025 | Form 4 ↗ same day · 11,000 shares | Form 144 ↗ |
| Nov 24, 2025 | Claire Mazumdar Officer | BCAX Bicara Therapeutics Inc. | 41,163 | $776.4K | 10b5-1 | Nov 24, 2025 | Form 4 ↗ 1 day later · 41,163 shares | Form 144 ↗ |
| Nov 24, 2025 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 17,795 | $330.1K | 10b5-1 | Nov 24, 2025 | Form 4 ↗ 1 day later · 18,400 shares | Form 144 ↗ |
| Nov 24, 2025 | David Raben Officer | BCAX Bicara Therapeutics Inc. | 5,500 | $101.5K | 10b5-1 | Nov 24, 2025 | Form 4 ↗ 1 day later · 11,000 shares | Form 144 ↗ |
| Nov 21, 2025 | Ivan Hyep Officer | BCAX Bicara Therapeutics Inc. | 605 | $11.0K | 10b5-1 | Nov 21, 2025 | Form 4 ↗ 4 days later · 18,400 shares | Form 144 ↗ |
| Nov 21, 2025 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 12,500 | $225.6K | 10b5-1 | Nov 21, 2025 | Form 4 ↗ 4 days later · 12,500 shares | Form 144 ↗ |
| Oct 16, 2025 | Claire Mazumdar Officer, Director | BCAX Bicara Therapeutics Inc. | 24,103 | $453.8K | 10b5-1 | Oct 16, 2025 | Form 4 ↗ 4 days later · 24,103 shares | Form 144 ↗ |
| Oct 15, 2025 | Ryan Cohlhepp Officer | BCAX Bicara Therapeutics Inc. | 12,500 | $226.6K | 10b5-1 | Oct 15, 2025 | Form 4 ↗ 1 day later · 12,500 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:03 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances